Immunologic Tumor Microenvironment Modulators for Turning Cold Tumors Hot

Overview

Journal Cancer Commun (Lond)

Publisher Wiley

Specialty Oncology

Date 2024 Mar 29

PMID 38551889

Authors

Gholam-Reza Khosravi

Samaneh Mostafavi

Sanaz Bastan

Narges Ebrahimi

Roya Safari Gharibvand

Nahid Eskandari

Affiliations

Soon will be listed here.

Abstract

Tumors can be classified into distinct immunophenotypes based on the presence and arrangement of cytotoxic immune cells within the tumor microenvironment (TME). Hot tumors, characterized by heightened immune activity and responsiveness to immune checkpoint inhibitors (ICIs), stand in stark contrast to cold tumors, which lack immune infiltration and remain resistant to therapy. To overcome immune evasion mechanisms employed by tumor cells, novel immunologic modulators have emerged, particularly ICIs targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1/programmed death-ligand 1(PD-1/PD-L1). These agents disrupt inhibitory signals and reactivate the immune system, transforming cold tumors into hot ones and promoting effective antitumor responses. However, challenges persist, including primary resistance to immunotherapy, autoimmune side effects, and tumor response heterogeneity. Addressing these challenges requires innovative strategies, deeper mechanistic insights, and a combination of immune interventions to enhance the effectiveness of immunotherapies. In the landscape of cancer medicine, where immune cold tumors represent a formidable hurdle, understanding the TME and harnessing its potential to reprogram the immune response is paramount. This review sheds light on current advancements and future directions in the quest for more effective and safer cancer treatment strategies, offering hope for patients with immune-resistant tumors.

Citing Articles

Targeting novel regulated cell death: disulfidptosis in cancer immunotherapy with immune checkpoint inhibitors.

Du F, Wang G, Dai Q, Huang J, Li J, Liu C Biomark Res. 2025; 13(1):35.

PMID: 40012016 PMC: 11866848. DOI: 10.1186/s40364-025-00748-4.

[TIM3+CD8+ T Cell Expression and Clinical Significance in the Central and Non-central Tumor Microenvironment of Non-small Cell Lung Cancer].

Wu J, Guo S, Lv L, Zhai J, Shen Y, Chen C Zhongguo Fei Ai Za Zhi. 2025; 27(12):903-910.

PMID: 39962845 PMC: 11839502. DOI: 10.3779/j.issn.1009-3419.2024.102.46.

Intra-Tumoral CD8+:CD3+ Lymphocyte Density Ratio in Appendix Cancer Is a Tumor Volume- and Grade-Independent Predictor of Survival.

Knotts C, Park H, Sherry C, Blodgett R, Lewis C, Omstead A Cancers (Basel). 2025; 17(3).

PMID: 39941908 PMC: 11817446. DOI: 10.3390/cancers17030542.

Optimizing rWTC-MBTA Vaccine Formulations, Dosing Regimens, and Cryopreservation Techniques to Enhance Anti-Metastatic Immunotherapy.

Ye J, Wang H, Chakraborty S, Sang X, Xue Q, Sun M Int J Mol Sci. 2025; 26(3).

PMID: 39941108 PMC: 11818183. DOI: 10.3390/ijms26031340.

IgG4-mediated M2 macrophage polarization in tertiary lymphoid structures of esophageal cancer: implications for immunosuppression.

Wang H, Li J, Wang Y, Chen Y, Zhang W, Pan X Front Immunol. 2025; 15:1497783.

PMID: 39896813 PMC: 11782137. DOI: 10.3389/fimmu.2024.1497783.

References

Sharma P, Hu-Lieskovan S, Wargo J, Ribas A . Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017; 168(4):707-723. PMC: 5391692. DOI: 10.1016/j.cell.2017.01.017. View

Calcinotto A, Spataro C, Zagato E, Di Mitri D, Gil V, Crespo M . IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature. 2018; 559(7714):363-369. PMC: 6461206. DOI: 10.1038/s41586-018-0266-0. View

Spranger S, Dai D, Horton B, Gajewski T . Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. Cancer Cell. 2017; 31(5):711-723.e4. PMC: 5650691. DOI: 10.1016/j.ccell.2017.04.003. View

Li X, Wenes M, Romero P, Huang S, Fendt S, Ho P . Navigating metabolic pathways to enhance antitumour immunity and immunotherapy. Nat Rev Clin Oncol. 2019; 16(7):425-441. DOI: 10.1038/s41571-019-0203-7. View

Chang C, Qiu J, OSullivan D, Buck M, Noguchi T, Curtis J . Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell. 2015; 162(6):1229-41. PMC: 4864363. DOI: 10.1016/j.cell.2015.08.016. View

Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

Wang S, Wang Z, Li Z, Xu J, Meng X, Zhao Z . A Catalytic Immune Activator Based on Magnetic Nanoparticles to Reprogram the Immunoecology of Breast Cancer from "Cold" to "Hot" State. Adv Healthc Mater. 2022; 11(21):e2201240. DOI: 10.1002/adhm.202201240. View

Shimabukuro-Vornhagen A, Draube A, Liebig T, Rothe A, Kochanek M, von Bergwelt-Baildon M . The immunosuppressive factors IL-10, TGF-β, and VEGF do not affect the antigen-presenting function of CD40-activated B cells. J Exp Clin Cancer Res. 2012; 31:47. PMC: 3443023. DOI: 10.1186/1756-9966-31-47. View

Socinski M, Jotte R, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N . Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018; 378(24):2288-2301. DOI: 10.1056/NEJMoa1716948. View

10.

Noguchi E, Shien T, Iwata H . Current status of PD-1/PD-L1 blockade immunotherapy in breast cancer. Jpn J Clin Oncol. 2020; 51(3):321-332. DOI: 10.1093/jjco/hyaa230. View

11.

Ma Z, Zhang W, Dong B, Xin Z, Ji Y, Su R . Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy. Theranostics. 2022; 12(11):4965-4979. PMC: 9274752. DOI: 10.7150/thno.73152. View

12.

Powles T, van der Heijden M, Castellano D, Galsky M, Loriot Y, Petrylak D . Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2020; 21(12):1574-1588. DOI: 10.1016/S1470-2045(20)30541-6. View

13.

Liu Y, Di S, Shi B, Zhang H, Wang Y, Wu X . Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3-Targeted Chimeric Antigen Receptor-Engineered T Cells in Hepatocellular Carcinoma. J Immunol. 2019; 203(1):198-207. DOI: 10.4049/jimmunol.1800033. View

14.

Pol J, Kroemer G . Anti-CTLA-4 immunotherapy: uncoupling toxicity and efficacy. Cell Res. 2018; 28(5):501-502. PMC: 5951874. DOI: 10.1038/s41422-018-0031-9. View

15.

de Visser K, Korets L, Coussens L . De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell. 2005; 7(5):411-23. DOI: 10.1016/j.ccr.2005.04.014. View

16.

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View

17.

Han J, Lim J, Wang C, Han J, Shin H, Kim S . Lipid nanoparticle-based mRNA delivery systems for cancer immunotherapy. Nano Converg. 2023; 10(1):36. PMC: 10406775. DOI: 10.1186/s40580-023-00385-3. View

18.

Mahatma G, Sweeney A, Yen M . Imiquimod for Superficial Basal Cell Carcinomas. Int Ophthalmol Clin. 2020; 60(2):3-11. DOI: 10.1097/IIO.0000000000000299. View

19.

Dhanasekaran R, Deutzmann A, Mahauad-Fernandez W, Hansen A, Gouw A, Felsher D . The MYC oncogene - the grand orchestrator of cancer growth and immune evasion. Nat Rev Clin Oncol. 2021; 19(1):23-36. PMC: 9083341. DOI: 10.1038/s41571-021-00549-2. View

20.

Argyle D, Kitamura T . Targeting Macrophage-Recruiting Chemokines as a Novel Therapeutic Strategy to Prevent the Progression of Solid Tumors. Front Immunol. 2018; 9:2629. PMC: 6243037. DOI: 10.3389/fimmu.2018.02629. View